Overview

Safety and Effectiveness of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2028-09-01

Target enrollment:

Participant gender:

Summary

This is a Phase III, multisite, randomized, double-blinded study to investigate BNT327 combined with chemotherapy (etoposide/carboplatin) compared to atezolizumab combined with chemotherapy (etoposide/carboplatin) for the treatment of participants with previously untreated extensive-stage small-cell lung cancer (ES-SCLC).

Phase:

PHASE3

Details

Lead Sponsor:

BioNTech SE

Collaborator:

Biotheus Inc.

Treatments:

atezolizumab
Carboplatin
Etoposide